Company intelligence / Profile preview

Medicrea

Rillieux-la-Pape, Auvergne-Rhone-Alpes, Francemedicrea.com ↗

Ownership: Private
Employees: ~190
Development stage: Commercial

Overview

Medicrea developed a commercial portfolio of over 30 FDA-cleared spinal implant technologies used in more than 175,000 surgeries. Its proprietary UNiD ASI platform leverages AI and big data to enable fully personalized spine surgery solutions. The company’s custom-designed interbody cages received multiple FDA clearances for patient-specific use. In November 2020, Medtronic completed its acquisition of Medicrea to integrate these capabilities into its global spine business.

Therapeutic areas: OtherNeurology
Modalities: Device (custom 3D printed titanium spinal implants)Software (AI-driven surgical planning tools)
Industry: Implantable Medical Devices

Partnerships

None specifically disclosed beyond clinical collaborations with surgeons; now part of Medtronic’s partner network post-acquisition.

Beyond the preview

Go deeper on Medicrea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medicrea.

Explore the full profile